Richard Nathan, DO
Infectious Disease · Idaho Falls, IDNPI 1942229570
Payments from drug & device makers
Across 393 payments — averaging $3497.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bavarian Nordic A/s$374K
- Sanofi Pasteur Inc.$365K
- Modernatx, Inc.$228K
- Novartis$162K
- Pfizer$86K
- BD$70K
- plus $89K from 15 others
Across 25 payments — averaging $1792.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- First Wave Biopharma, Inc.$43K
- Sanofi Pasteur Inc.$2K
- Sanofi US Services Inc.$45
What the payments were for
- Travel & lodging$2,94158%
- Food & beverage$2,01040%
- Education$1363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bavarian Nordic A/s | 73 | $374,246 |
| Sanofi Pasteur Inc. | 85 | $365,240 |
| Modernatx, Inc. | 80 | $227,782 |
| Novartis | 2 | $161,812 |
| Pfizer | 28 | $86,450 |
| BD | 1 | $69,615 |
| Sanofi US Services Inc. | 16 | $40,459 |
| GSK | 12 | $30,674 |
| AstraZeneca | 4 | $12,177 |
| First Wave Biopharma, Inc. | 1 | $4,529 |
| AbbVie(2 entities) | 51 | $544 |
| Melinta Therapeutics, LLC | 11 | $240 |
| Merck | 11 | $189 |
| Astellas Pharma US Inc | 5 | $112 |
| Insmed, Inc. | 2 | $80 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $56 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| La Jolla Pharmaceutical Company | 2 | $43 |
| Gilead | 2 | $36 |
| Shionogi Inc | 1 | $26 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$1,306
How this compares
$1,374,375 in reported general payments places this provider in the 95th percentile of 29 infectious disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 54 | $25,805 |
| ErtapenemErtapenem Sodium | 25 | $13,847 |
| Sodium Chloride0.9 % Sodium Chloride | 47 | $1,411 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 52 | $1,168 |
| Cefdinir | 11 | $886 |
| Clindamycin Hcl | 30 | $532 |
| Fluconazole | 38 | $440 |
| Cephalexin | 33 | $424 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $405 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $329 |
| Cefadroxil | 14 | $278 |
| Doxycycline Hyclate | 18 | $158 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Idaho Falls
- Martha BuitragoIdaho Falls$1.7M
- John BagwellIdaho Falls$149
- David PomboIdaho Falls$47
- John HammerBoise$605K
- Sean Tristan CookCoeur D Alene$249K
- Sugat PatelNampa$37K
- Sky BlueBoise$2K
- Thomas CoffmanBoise$838
- Sarah ShewayishBoise$769
- Quentin DoperalskiBoise$516
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.